Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo Controlled, Two-Period Cross-Over, Proof of Activity Study to Evaluate the Effects of TAK-041 on Motivational Anhedonia as Add-On to Antipsychotics in Subjects With Stable Schizophrenia

Next Previous
X
Search
Trial Profile

A Randomized, Double-Blind, Placebo Controlled, Two-Period Cross-Over, Proof of Activity Study to Evaluate the Effects of TAK-041 on Motivational Anhedonia as Add-On to Antipsychotics in Subjects With Stable Schizophrenia

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 22 Mar 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs TAK 041 (Primary) ; Asenapine; Iloperidone; Lurasidone; Olanzapine; Paliperidone; Quetiapine; Risperidone; Ziprasidone
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Sponsors Takeda

    • Most Recent Events

    • 20 Jan 2021 All participants received a stable dose of antipsychotics as per standard of care throughout the duration of the Treatment Period. Number of treatment arms increased from 2 to 4.
    • 17 Oct 2020 This trial is discontinued (Global End Date: 06 Nov 2019), according to European Clinical Trials Database record.
    • 12 Nov 2019 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top